Arrayit joins federal government to help control health care costs through early diagnosis of diseases

Arrayit Corporation (OTCBB: ARYC) is pleased to join the federal government in their efforts to help control health care costs through early diagnosis of diseases.

For more than 150 years, traditional medicine has relied on a 'standards of care' model, which utilizes large cohorts of individuals as the data set and essentially treats every person in an identical manner. While this medical model provides a good paradigm for standard health care practices, it is woefully deficient in that it fails to include genetic and epigenetic differences between people as well as the interplay between our genes and environmental factors including medication, diet and other lifestyle considerations. In a major paradigm shift, personalized medicine is gaining rapid popularity in that it endeavors to provide customized health care to individuals inclusive of genetics, epigenetics and the environment, leading to early stage diagnosis of diseases that have exacted a heavy cost in quality and length of life and dollars spent in late stage treatment.

Personalized medicine is a vastly superior advance in health care if it can be delivered at a rate equivalent to or less than the current standards of care model. As a next generation health care company, Arrayit Corporation is capable of delivering personalized medical information to the public at a fraction of current costs, owing to the company's unique ability to miniaturize, automate and massively parallelize genomic and proteomic tests. In simple terms, these molecular diagnostic tests, requiring only a blood sample, will be more accurate and less personally invasive than many traditional cancer screening methods. Arrayit's patented microarray manufacturing technology and Variation Identification Platform (VIP) procedures, deployed in clinical laboratories and reference centers, are capable of testing entire population groups. Arrayit personalized medical tests for pre-symptomatic ovarian cancer detection, H1N1 screening, and Parkinson's Disease diagnostics represent only a few of the collaborative milestones soon to be announced.